漢邦高科(300449.SZ)擬1元出售虧損子公司銀河偉業100%股權
格隆匯6月17日丨漢邦高科(300449.SZ)公佈,北京銀河偉業數字技術有限公司(以下簡稱“銀河偉業”或“目標公司”)是公司的全資子公司。公司擬以1元的價格出售虧損全資子公司銀河偉業100%股權給湖南全通智能科技有限公司(以下稱“受讓方”或“湖南全通”)。交易完成後,銀河偉業將不再納入公司合併報表範圍。
公司出售銀河偉業,剝離虧損業務單元,有助於整合及優化現有資源配置,聚焦公司核心業務,提升上市公司整體競爭力,公司董事會將積極關注並追償財務資助款項。財務資助的風險處於可控制範圍內,不會對公司的日常經營產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.